Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01082250 · ClinicalTrials.gov registry record · Phase 1
The Bioequivalence Of Two Different Lurasidone Formulations In Patients
A Phase 1 study, sponsored by Sumitomo Pharma America.
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT01082250: Completed Phase 1 study, sponsored by Sumitomo Pharma America.
NCT01082250 is a Phase 1 study that has completed, run by Sumitomo Pharma America. The registered enrollment target is 52 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01082250, a Phase 1 study, has completed, sponsored by Sumitomo Pharma America.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl
Interventions
- DRUG Lurasidone HCl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2008-07 |
| Est. Completion | 2008-09 |
| Phase | Phase 1 |
What the finished NCT01082250 record still lists
NCT01082250 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 52 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 1 intervention - of which Lurasidone HCl is the first listed.
NCT01082250 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01082250 about?
NCT01082250 is a clinical study titled "The Bioequivalence Of Two Different Lurasidone Formulations In Patients". A Phase I, Bioequivalent Study between 2 Formulations of Lurasidone HCl
What is the current status of trial NCT01082250?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2008-07. Estimated completion is 2008-09.
What interventions are being tested in trial NCT01082250?
The interventions under investigation include: Lurasidone HCl (DRUG).
Who is sponsoring clinical trial NCT01082250?
This trial is sponsored by Sumitomo Pharma America, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01082250's enrollment target sits among peer trials
52 956th of 2000 higher than 1,032 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02630121 · 52 participants · Phase 4
Effect of Oxymetazoline Hydrochloride in Combination With Fluticasone Propionate on the Apnea Hypopnea Index (AHI) in Subject With Persistent Nasal Congestion and Mild Obstructive Sleep Apnea
- NCT03629171 · 52 participants · Phase 2
Liposome-encapsulated Daunorubicin-Cytarabine and Venetoclax in Treating Participants With Relapsed, Refractory or Untreated Acute Myeloid Leukemia
- NCT04128748 · 52 participants · Phase 1
Liposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome
- NCT04150497 · 52 participants · Phase 1
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia